# A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)

> **NCT05566990** · PHASE3 · COMPLETED · sponsor: **SK Plasma Co., Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **BIOLOGICAL:** LIV-GAMMA SN Inj.10%

## Key facts

- **NCT ID:** NCT05566990
- **Lead sponsor:** SK Plasma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-19
- **Primary completion:** 2021-06-03
- **Final completion:** 2021-11-26
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05566990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05566990, "A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05566990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*